| Literature DB >> 35628304 |
Lin Zhang1, Shubo Wang1, Wenmeng Wang1, Jinming Shi1, Daniel B Stovall2, Dangdang Li1, Guangchao Sui1.
Abstract
In live cells, proteins and nucleic acids can associate together through multivalent interactions, and form relatively isolated phases that undertake designated biological functions and activities. In the past decade, liquid-liquid phase separation (LLPS) has gradually been recognized as a general mechanism for the intracellular organization of biomolecules. LLPS regulates the assembly and composition of dozens of membraneless organelles and condensates in cells. Due to the altered physiological conditions or genetic mutations, phase-separated condensates may undergo aberrant formation, maturation or gelation that contributes to the onset and progression of various diseases, including neurodegenerative disorders and cancers. In this review, we summarize the properties of different membraneless organelles and condensates, and discuss multiple phase separation-regulated biological processes. Based on the dysregulation and mutations of several key regulatory proteins and signaling pathways, we also exemplify how aberrantly regulated LLPS may contribute to human diseases.Entities:
Keywords: human diseases; liquid–liquid phase separation (LLPS); membraneless organelles; phase-separated condensates
Mesh:
Substances:
Year: 2022 PMID: 35628304 PMCID: PMC9141834 DOI: 10.3390/ijms23105491
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1Schematic diagram of membraneless organelles and their functions in a eukaryotic cell.
Membraneless organelles and condensates assembled through the LLPS mechanism.
| Localization | Name | Alias | Size (nm) | Components | Functions | Diseases | References |
|---|---|---|---|---|---|---|---|
| Cytoplasm | P-body | GW-body, RNA processing body, decapping body | 100–300 | K63, TRAF6, Tob1, TUT4, NoBody, | mRNA degradation, post-transcriptional gene silencing, response to stress, storage of translationally repressed mRNAs | viral infection, neurodegenerative diseases, autoimmune | [ |
| Stress granule | — | 1000–2000 | RBPs, non-RBPs, | translational regulation, | amyotrophic lateral sclerosis, frontotemporal lobar degeneration, | [ | |
| Germ granule | P-granule, | 250–4000 | MEG-3, PGL, RNA, | post-transcriptional regulation, | Germ cell development | [ | |
| Synaptic density | Postsynaptic density | 500 | PSD-95, GKAP, | responsible for signal processing | neuropsychiatric diseases | [ | |
| RNA transport | Neuronal RNA granule | 500–1000 | Sam68, RNG105, SMN, etc. | mRNA storage and | neurodegenerative diseases | [ | |
| Balbiani Body | Balbiani’s vesicle, the yolk body of Balbiani, yolk nucleus | 50–250,000 | RNA, mitochondria, | store RNA, proteins and | — | [ | |
| Sec body | — | 1000 | COPII components, Sec16, etc. | response to the nutrient | — | [ | |
| U-body | Uridine-rich snRNP body | 500 | SnRNP, SMN, etc. | storage and assembly of snRNPs | spinal muscular atrophy | [ | |
| PSG | — | 500 | proteasomes, | protein-specific degradation, | aging and age-related disease | [ | |
| Signaling puncta | Dvl puncta | 500–1000 | Dvl-2, etc. | signal transduction | — | [ | |
| Metabolic granule | G-body | 1000–5000 | glycolytic enzymes, | glycolysis and storage | — | [ | |
| STAT3 cytoplasmic body | STAT3 sequestering endosomes | — | STAT3 | prolongation of signaling and/or cross talk | hepatoma | [ | |
| TIS granule | — | 1000–5000 | TIS11B, membrane protein-encoding | 3′UTR-dependent nurturing of nascent proteins | — | [ | |
| Nuclear | Nuclear pore | — | 40–100 | nucleoporins, NDC1, GP210, POM121 | facilitate nucleocytoplasmic transport, chromatin organization | neurological disorders and the aging brain, viral infections and immunity, the development and progression of cancers | [ |
| Nucleus | Nucleolus | — | 1000–10,000 | Nucleolin, | ribosome biogenesis | Werner syndrome, | [ |
| HLB | — | 1000 | NPAT, FLASH, SLBP, p220NPAT, NELF, symplekin, etc. | processing of the histone | breast cancer | [ | |
| DNA damage foci | — | 500 | γH2AX, ATM, 53BP1, RAD51, etc. | response to DNA damage | neurodegenerative diseases | [ | |
| PML body | PML oncogenic domain, | 250–500 | UBC9, RNF4, SP100, P53, DAXX, SUMO, PML, RNF168, etc. | transcription regulation, apoptosis signaling, | Acute Promyelocytic Leukemia, liver fibrosis | [ | |
| Nuclear stress | Peroxisome granule (PG) | 300–3000 | HSF1, HAP, SAM68, | response to stress, control of gene expression and RNA splicing activities | metabolic syndrome | [ | |
| Cajal body | accessory body | 100–2000 | RNA, snRNPs, | pre-mRNA and pre-rRNA processing | amyotrophic lateral sclerosis, spinal muscular atrophy | [ | |
| PcG body | — | 200–1500 | PRC1, PRC2, EZH2, etc. | transcriptional repression | malignant lymphomas, epithelial tumors | [ | |
| CNB | — | 1000–3000 | CBP, SUMO-1, etc. | response to DNA damage, | — | [ | |
| Paraspeckle | — | 500–1000 | CTN-RNA, PSP1, p54nrb, NEAT1, NONO, etc. | regulate gene expression, | breast cancer, hepatocellular carcinoma, viral infection, neurodegenerative diseases | [ | |
| PNC | — | 250–4000 | CUGBP, KSRP, polymerase III, | transcriptional regulation, | breast cancer, | [ | |
| Nuclear gem | Gemini of Cajal body, Gemini | 100–2000 | SMN, etc. | mRNA processing | spinal muscular atrophy | [ | |
| OPT domain body | 53P1-OPT domain | 1000–1500 | Nascent mRNA, transcription factors, | transcriptional regulation, | — | [ | |
| STAT3 nuclear body | — | — | STAT3, CREB binding protein (CBP), acetylated histone H4 | activation of target genes | hepatoma | [ | |
| Nucleolus | Amyloid body | A-body | 500–2000 | Amyloid beta peptides, etc. | store proteins | neurodegenerative diseases | [ |
PSG: Proteasome storage granule; HLB: Histone locus body; PML: Promyelocytic Leukemia; PcG: Polycomb group; CNB: SUMO-1 nuclear body; PNC: Perinucleolar compartment; OPT: OCT1/PTF/transcription.
Figure 2Regulation of gene expression by the phase-separation mechanism.